IMPORTANCE: Attention-deficit/hyperactivity disorder (ADHD) research has long focused on the dopaminergic system's contribution to pathogenesis, although the results have been inconclusive. However, a case has been made for the involvement of the noradrenergic system, which modulates cognitive processes, such as arousal, working memory, and response inhibition, all of which are typically affected in ADHD. Furthermore, the norepinephrine transporter (NET) is an important target for frequently prescribed medication in ADHD. Therefore, the NET is suggested to play a critical role in ADHD. OBJECTIVE: To explore the differences in NET nondisplaceable binding potential (NET BPND) using positron emission tomography and the highly selective radioligand (S,S)-[18F]FMeNER-D2 [(S,S)-2-(α-(2-[18F]fluoro[2H2]methoxyphenoxy)benzyl)morpholine] between adults with ADHD and healthy volunteers serving as controls. DESIGN, SETTING, AND PARTICIPANTS: Twenty-two medication-free patients with ADHD (mean [SD] age, 30.7 [10.4] years; 15 [68%] men) without psychiatric comorbidities and 22 age- and sex-matched healthy controls (30.9 [10.6] years; 15 [68%] men) underwent positron emission tomography once. A linear mixed model was used to compare NET BPND between groups. MAIN OUTCOMES AND MEASURES: The NET BPND in selected regions of interest relevant for ADHD, including the hippocampus, putamen, pallidum, thalamus, midbrain with pons (comprising a region of interest that includes the locus coeruleus), and cerebellum. In addition, the NET BPND was evaluated in thalamic subnuclei (13 atlas-based regions of interest). RESULTS: We found no significant differences in NET availability or regional distribution between patients with ADHD and healthy controls in all investigated brain regions (F1,41<0.01; P=.96). Furthermore, we identified no significant association between ADHD symptom severity and regional NET availability. Neither sex nor smoking status influenced NET availability. We determined a significant negative correlation between age and NET availability in the thalamus (R2=0.29; P<.01 corrected) and midbrain with pons, including the locus coeruleus (R2=0.18; P<.01 corrected), which corroborates prior findings of a decrease in NET availability with aging in the human brain. CONCLUSIONS AND RELEVANCE: Our results do not indicate involvement of changes in brain NET availability or distribution in the pathogenesis of ADHD. However, the noradrenergic transmitter system may be affected on a different level, such as in cortical regions, which cannot be reliably quantified with this positron emission tomography ligand. Alternatively, different key proteins of noradrenergic neurotransmission might be affected.
IMPORTANCE: Attention-deficit/hyperactivity disorder (ADHD) research has long focused on the dopaminergic system's contribution to pathogenesis, although the results have been inconclusive. However, a case has been made for the involvement of the noradrenergic system, which modulates cognitive processes, such as arousal, working memory, and response inhibition, all of which are typically affected in ADHD. Furthermore, the norepinephrine transporter (NET) is an important target for frequently prescribed medication in ADHD. Therefore, the NET is suggested to play a critical role in ADHD. OBJECTIVE: To explore the differences in NET nondisplaceable binding potential (NET BPND) using positron emission tomography and the highly selective radioligand (S,S)-[18F]FMeNER-D2 [(S,S)-2-(α-(2-[18F]fluoro[2H2]methoxyphenoxy)benzyl)morpholine] between adults with ADHD and healthy volunteers serving as controls. DESIGN, SETTING, AND PARTICIPANTS: Twenty-two medication-free patients with ADHD (mean [SD] age, 30.7 [10.4] years; 15 [68%] men) without psychiatric comorbidities and 22 age- and sex-matched healthy controls (30.9 [10.6] years; 15 [68%] men) underwent positron emission tomography once. A linear mixed model was used to compare NET BPND between groups. MAIN OUTCOMES AND MEASURES: The NET BPND in selected regions of interest relevant for ADHD, including the hippocampus, putamen, pallidum, thalamus, midbrain with pons (comprising a region of interest that includes the locus coeruleus), and cerebellum. In addition, the NET BPND was evaluated in thalamic subnuclei (13 atlas-based regions of interest). RESULTS: We found no significant differences in NET availability or regional distribution between patients with ADHD and healthy controls in all investigated brain regions (F1,41<0.01; P=.96). Furthermore, we identified no significant association between ADHD symptom severity and regional NET availability. Neither sex nor smoking status influenced NET availability. We determined a significant negative correlation between age and NET availability in the thalamus (R2=0.29; P<.01 corrected) and midbrain with pons, including the locus coeruleus (R2=0.18; P<.01 corrected), which corroborates prior findings of a decrease in NET availability with aging in the human brain. CONCLUSIONS AND RELEVANCE: Our results do not indicate involvement of changes in brain NET availability or distribution in the pathogenesis of ADHD. However, the noradrenergic transmitter system may be affected on a different level, such as in cortical regions, which cannot be reliably quantified with this positron emission tomography ligand. Alternatively, different key proteins of noradrenergic neurotransmission might be affected.
Authors: Samuel R Chamberlain; Trevor W Robbins; Sophie Winder-Rhodes; Ulrich Müller; Barbara J Sahakian; Andrew D Blackwell; Jennifer H Barnett Journal: Biol Psychiatry Date: 2010-11-03 Impact factor: 13.382
Authors: Craig W Berridge; David M Devilbiss; Matthew E Andrzejewski; Amy F T Arnsten; Ann E Kelley; Brooke Schmeichel; Christina Hamilton; Robert C Spencer Journal: Biol Psychiatry Date: 2006-06-23 Impact factor: 13.382
Authors: Danielle C Turner; Andrew D Blackwell; Jonathan H Dowson; Andrew McLean; Barbara J Sahakian Journal: Psychopharmacology (Berl) Date: 2004-08-27 Impact factor: 4.530
Authors: William J Barbaresi; Robert C Colligan; Amy L Weaver; Robert G Voigt; Jill M Killian; Slavica K Katusic Journal: Pediatrics Date: 2013-03-04 Impact factor: 7.124
Authors: Yu-Shin Ding; Tarun Singhal; Beata Planeta-Wilson; Jean-Dominique Gallezot; Nabeel Nabulsi; David Labaree; Jim Ropchan; Shannan Henry; Wendol Williams; Richard E Carson; Alexander Neumeister; Robert T Malison Journal: Synapse Date: 2010-01 Impact factor: 2.562
Authors: Swen Hesse; Georg-Alexander Becker; Michael Rullmann; Anke Bresch; Julia Luthardt; Mohammed K Hankir; Franziska Zientek; Georg Reißig; Marianne Patt; Katrin Arelin; Donald Lobsien; Ulrich Müller; S Baldofski; Philipp M Meyer; Matthias Blüher; Mathias Fasshauer; Wiebke K Fenske; Michael Stumvoll; Anja Hilbert; Yu-Shin Ding; Osama Sabri Journal: Eur J Nucl Med Mol Imaging Date: 2017-01-09 Impact factor: 9.236
Authors: Thomas Vanicek; Alexandra Kutzelnigg; Cecile Philippe; Helen L Sigurdardottir; Gregory M James; Andreas Hahn; Georg S Kranz; Anna Höflich; Alexander Kautzky; Tatjana Traub-Weidinger; Marcus Hacker; Wolfgang Wadsak; Markus Mitterhauser; Siegfried Kasper; Rupert Lanzenberger Journal: Hum Brain Mapp Date: 2016-10-22 Impact factor: 5.038
Authors: A Kautzky; G M James; C Philippe; P Baldinger-Melich; C Kraus; G S Kranz; T Vanicek; G Gryglewski; W Wadsak; M Mitterhauser; D Rujescu; S Kasper; R Lanzenberger Journal: Transl Psychiatry Date: 2017-06-13 Impact factor: 6.222
Authors: Gregory M James; Pia Baldinger-Melich; Cecile Philippe; Georg S Kranz; Thomas Vanicek; Andreas Hahn; Gregor Gryglewski; Marius Hienert; Marie Spies; Tatjana Traub-Weidinger; Markus Mitterhauser; Wolfgang Wadsak; Marcus Hacker; Siegfried Kasper; Rupert Lanzenberger Journal: Front Hum Neurosci Date: 2017-02-06 Impact factor: 3.169
Authors: Helen L Sigurdardottir; Georg S Kranz; Christina Rami-Mark; Gregory M James; Thomas Vanicek; Gregor Gryglewski; Alexander Kautzky; Marius Hienert; Tatjana Traub-Weidinger; Markus Mitterhauser; Wolfgang Wadsak; Marcus Hacker; Dan Rujescu; Siegfried Kasper; Rupert Lanzenberger Journal: Hum Brain Mapp Date: 2015-12-17 Impact factor: 5.038